Biologics to Treat Substance Use Disorders, Softcover reprint of the original 1st ed. 2016 Vaccines, Monoclonal Antibodies, and Enzymes

This book is a scientific compendium documenting the state of the art in the discovery and development of vaccines, monoclonal antibodies, and enzymes for the treatment of Substance Use Disorders (SUDs). The book gives detailed consideration to some of the most cutting edge topics in addiction medicine, including vaccines for nicotine, cocaine, heroin, and methamphetamine dependence; monoclonal antibodies against cocaine, methamphetamine, and phencyclidine; and the enzymes butyrylcholinesterase and cocaine esterase. In addition, the text covers a wide range of new strategies designed to optimize the development and efficacy of biologics. Unlike any other resource, this book reviews how biologics offer exciting new therapeutic opportunities for various psychiatric conditions.

Written by experts in the field, Biologics to Treat Substance Use Disorders is as an authoritative reference for psychiatrists, psychologists, and all other medical professionals working with patients suffering from Substance Use Disorders.

Introduction

Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes

Phil Skolnick

Section 1.  Vaccines

Matthew W. Kalnik, Ph.D.

Vaccines for Treating Cocaine Use Disorders

Coreen B. Domingo;  Daryl Shorter; Thomas R. Kosten  

Vaccines for Opioid Addiction

Vaccines for Methamphetamine Use Disorder

Thomas R. Kosten and Therese A. Kosten

Vaccine for Cocaine Addiction and HIV infection

Timothy Cardozo, Sergey Shmelkov, Kenneth Ca

Section 2. Monoclonal antibodies

Monoclonal Antibodies: Introduction

S. Michael Owens

Anti-cocaine monoclonal antibodies

Discovery and Development of an Anti-methamphetamine Monoclonal Antibody for use in Treating Methamphetamine Abuse

Michael D. Hambuchen, Misty W. Stevens, Melinda G. Gunnell, W. Brooks Gen-try, and S. Michael Owens

Enzyme-based cocaine pharmacotherapies: Current status and projections for the future. 

James H. Woods, Chang-Guo Zhan

W. Steve Brimijoin Cocaine Hydrolases Designed from Butyrylcholinesterase

Fang Zheng and Chang-Guo Zhan                                                                                                                    

Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders

David F. Havlicek, Jonathan B. Rosenberg, Dolan Sondhi, Ronald G. Crystal

and Stephen M. Kaminsky

Nanotechnology based nicotine vaccine

Petr O. Ilyinskii and Lloyd P.M. Johnston

Exploration of DNA nanostructures for rational design of vaccines

Xiaowei Liu, Sidney M. H

Adjuvants for Substance Abuse Vaccines

 Frank M. Orson, Berma M. Kinsey, Muthu Ramakrishnan, Reetakshi Arora, Thomas R. Kosten

Skin Vaccination against Nicotine Addiction

Xinyuan Chen, Ji Wang, Jeffrey H. Wu, and Mei X. Wu

Hapten design for anti-addiction vaccine development

Karen C. Collins, Kim D. Janda

B cell mechanisms underlying vaccine efficacy against drugs of abuse

 Marco Pravetoni, Ph.D.

Section 5. Practical Considerations

Practical considerations for the development of vaccines against drugs of abuse

Oscar B. Torres, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice and

Ethical Aspects of Biologics to Treat Substance Use Disorders

Ivan D. Montoya

Covers all aspects of vaccines and other biologics employed for treatment of substance use disorders

Discusses novel strategies to optimize the development and efficacy of biologics

Written and edited by experts in the field